Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the announcement of encouraging trial results. With the stock currently trading at $0.

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Veru Inc. Currently has a Zacks ...

Barclays PLC lifted its position in shares of Veru Inc. (NASDAQ:VERU – Free Report) by 309.2% during the 3rd quarter, ...

InvestingPro data shows the stock has demonstrated strong resilience, often moving independently of broader market trends. The focus is on the potential of enobosarm, Veru's investigational drug, to ...